Conversion of Twice-Daily Tacrolimus to Once-Daily Tacrolimus Formulation in Stable Pediatric Kidney Transplant Recipients: Pharmacokinetics and Efficacy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Min, S. I. | - |
dc.contributor.author | Ha, J. | - |
dc.contributor.author | Kang, H. G. | - |
dc.contributor.author | Ahn, S. | - |
dc.contributor.author | Park, T. | - |
dc.contributor.author | Park, D. D. | - |
dc.contributor.author | Kim, S. M. | - |
dc.contributor.author | Hong, H. J. | - |
dc.contributor.author | Min, S. K. | - |
dc.contributor.author | Ha, I. S. | - |
dc.contributor.author | Kim, S. J. | - |
dc.date.accessioned | 2024-01-09T14:32:41Z | - |
dc.date.available | 2024-01-09T14:32:41Z | - |
dc.date.issued | 2013-08 | - |
dc.identifier.issn | 1600-6135 | - |
dc.identifier.issn | 1600-6143 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/70451 | - |
dc.description.abstract | The pharmacokinetics, efficacy and safety of once-daily tacrolimus formulation (Tac-OD) were assessed in 34 stable pediatric kidney transplant recipients. Enrolled patients received their dose of twice-daily tacrolimus formulation (Tac-BID) on study Days 0 through 7. On the morning of study Day 8, the total daily doses for patients were converted to Tac-ODon a 1:1 basis and maintained on a once-daily morning dosing regimen. Tacrolimus pharmacokinetic profiles were obtained on study Days 7, 14 and 28 (after dose adjustment). Although the mean C-0 concentrations (4.10 +/- 1.16-3.53 +/- 1.10 ng/mL, p = 0.004), and AUC(0-24) (151.8 +/- 41.6-129.8 +/- 39.3 ng h/mL, p < 0.001) were decreased significantly after a 1:1 based conversion, there was high interindividual variability. The dose of Tac-OD was decreased in 26.5% and increased in 44.1% of patients. The resultant tacrolimus dose and pharmacokinetic profiles on study Day 28 were comparable to those on Day 7. There were no serious adverse events. In conclusion, Tac-BID can be safely converted to Tac-OD in stable pediatric kidney transplant patients with the heightened therapeutic drug monitoring. Effects of drug conversion on the cardiovascular risk factors, neurological side effects and adherence should be further evaluated. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Conversion of Twice-Daily Tacrolimus to Once-Daily Tacrolimus Formulation in Stable Pediatric Kidney Transplant Recipients: Pharmacokinetics and Efficacy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/ajt.12274 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF TRANSPLANTATION, v.13, no.8, pp 2191 - 2197 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000322330000032 | - |
dc.identifier.scopusid | 2-s2.0-84881372386 | - |
dc.citation.endPage | 2197 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 2191 | - |
dc.citation.title | AMERICAN JOURNAL OF TRANSPLANTATION | - |
dc.citation.volume | 13 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Conversion | - |
dc.subject.keywordAuthor | pediatric kidney transplantation | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordAuthor | tacrolimus | - |
dc.subject.keywordPlus | DAILY PROGRAF | - |
dc.subject.keywordPlus | RENAL-TRANSPLANTATION | - |
dc.subject.keywordPlus | RELEASE FORMULATION | - |
dc.subject.keywordPlus | PROLONGED-RELEASE | - |
dc.subject.keywordPlus | ADHERENCE | - |
dc.subject.keywordPlus | NONADHERENCE | - |
dc.subject.keywordPlus | REGIMEN | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | TERM | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalResearchArea | Transplantation | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.relation.journalWebOfScienceCategory | Transplantation | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.